PEGylated Lipidic Nanocapsules Encapsulating Olaparib for Breast Cancer Therapy: In Vitro and In Vivo Evaluation

Multifunctional nanoparticles for co-delivery of elacridar and paclitaxel for breast cancer local treatment.

In an in vivo model of breast cancer, intraductal H-NPs reduced tumor incidence and volume compared to a drug solution, and increased the mammary tissue-to-plasma ratio of paclitaxel by 105-fold, supporting an improved tissue retention, support H-NPs as promising platforms for localized breast cancer therapy.

Repurposed Axitinib delivered via lipid-extruded PEGylated liposomes: 2D/3D breast cancer cell evaluation and in-vivo pharmacokinetics.

PEGylated liposomal nanocarriers have emerged as a promising drug delivery platform for improving the pharmacokinetic performance and systemic circulation of poorly water-soluble anticancer drugs. In this study, Axitinib-loaded PEGylated liposomes (F11-PEGliposome) were prepared and evaluated for the potential treatmen...

Liposomes-enabled gemcitabine therapy for breast cancer: in vitro and in vivo studies.

The nasal GLDL spray is anticipated to be a promising and effective treatment option for BC by developing a nasal spray containing GCN-loaded liposomes (GLDL), and exhibited antiproliferative properties, as demonstrated by histopathological analysis of the formulation.

Cationic Lipid Nanoparticles for Co-Encapsulation of Etoposide and Carboplatin: Formulation, Characterization, and In Vitro Evaluation

Engineered Multifunctional Nanococktail of Sorafenib for Targeted Therapy in Hepatic Cancer: In Vivo Study

SNC is established as a safe and effective nanocarrier system, capable of improving sorafenib bioavailability and reducing toxicity for enhanced HCC management.

Design, Development, and Characterization of Carmustine-Loaded Nanostructured Lipid Carriers for Enhanced Brain Accumulation and Antitumor Efficacy in Glioblastoma

In-vivo studies showed a reduction in tumor volume, increased accumulation of the drug in the brain, and enhanced antioxidant enzyme levels, with favorable pharmacokinetics, indicating that the nanoparticles are a promising system for the management of glioblastoma.